• Maria Cristina Colanardi, Eustachio Nettis, Pierluigi Traetta, Carmela Daprile, Carmela Fitto, Anna Maria Aloia, Elisabetta Di Leo, Antonio Ferrannini, and Angelo Vacca.
• Department of Medical Clinic, Immunology and Infectious Diseases, Division of Allergy and Clinical Immunology, University of Bari, Bari, Italy.
• Ann. Allergy Asthma Immunol. 2008 Jan 1; 100 (1): 82-5.

BackgroundParecoxib is the first injectable cyclooxygenase 2 selective inhibitor indicated for the treatment of acute postoperative pain.ObjectiveTo describe the results of a challenge with parecoxib in patients with a history of urticaria or angioedema to 1 or more nonsteroidal anti-inflammatory drugs (NSAIDs).MethodsThe study was performed from October 1, 2006, through March 31, 2007, with 79 patients who historically had experienced urticaria or angioedema after use of NSAIDs. The patients underwent a single-blind challenge with parecoxib, 40 mg.ResultsNo reaction to placebo was observed in any patient. Similarly, no reaction to parecoxib was observed in any patients in the single-class or multiple-class intolerance group.ConclusionOur report demonstrates that parecoxib does not induce cross-reactivity in patients with a history of urticaria or angioedema. Hence, this finding suggests that this drug could be safely proposed as an alternative (but only after a prior challenge) in patients with previous hypersensitive reactions to NSAIDs, even if there are added risk factors such as atopy and antimicrobial allergy, who require an analgesic drug perioperatively.

30 keywords...

hide…